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Summary. Background and objective: As activated thrombin-
activatable fibrinolysis inhibitor (TAFIa) is a potent antifibrin-
olytic enzyme, the development of TAFI inhibitors is a new
promising approach in the development of profibrinolytic
drugs. We, therefore, aimed to generate nanobodies, camelid-
derived single-domain antibodies towards TAFI.Methods and
results: This study reports the generation and characterization
of a panel of 22 inhibitory nanobodies. This panel represents a
wide diversity in mechanisms for interference with the func-
tional properties of TAFI as the nanobodies interfere with
various modes of TAFI activation, TAFIa activity and/or
TAFI zymogen activity. Nanobodies inhibiting TAFIa activity
and thrombin/thrombomodulin-mediated TAFI activation
revealed profibrinolytic properties in a clot lysis experiment
with exogenously added thrombomodulin (TM), whereas
nanobodies inhibiting plasmin-mediated TAFI activation only
revealed profibrinolytic properties in a clot lysis experiment
without TM. The results of in vitro clot lysis experiments
provided evidence that inhibitory nanobodies penetrate the clot
better compared with inhibitory monoclonal antibodies. Con-
clusions: These data suggest that the generated nanobodies are
potent TAFI inhibitors and are a step forward in the
development of a profibrinolytic drug. They might also be an
excellent tool to unravel the role of the physiological activators
of TAFI in various pathophysiological processes.
Keywords: fibrinolysis, inhibition, nanobodies, TAFI, profi-
brinolytic.
Introduction
Thrombin activatable fibrinolysis inhibitor (TAFI), also
known as procarboxypeptidase U (proCPU), forms a link
between coagulation and fibrinolysis. TAFI is synthesized by
the liver and circulates in plasma as a zymogen of 56 kDa [1–3].
The zymogen is activated by thrombin, thrombin/thrombo-
modulin (T/TM) or plasmin, resulting in the activation peptide
(AP; Phe1-Arg92; 20 kDa) and the catalytic domain TAFIa
(Ala93-Val401; 36 kDa, CPU) [1,4,5]. TAFIa attenuates fibri-
nolysis by removing surface-exposed C-terminal lysine residues
from fibrin, which are required for a positive feedback in
plasmin generation [6]. This mechanism provides the rationale
for inhibiting either the activation of TAFI or the TAFIa
activity, in order to enhance clot lysis. Furthermore, elevated
TAFI(a) levels are considered to be a risk factor for deep vein
thrombosis, angina pectoris and coronary artery disease [7,8].
In addition, the broad substrate specificity of TAFIa (e.g.
bradykinin, anaphylatoxines C3a and C5a and fibrin) leads to
additional roles of TAFI in the modulation of blood pressure,
cell migration and inflammation [9–12].
Previous studies demonstrated that co-infusion of a TAFIa
inhibitor, isolated from the potato tuber (PTCI), enhanced
the apparent potency of t-PA 3-fold in rabbit thrombosis
models [13,14]. Similarly, in an arterio-venous shunt model
of thrombosis in rat, thrombolysis was observed when a
TAFIa inhibitor was added whereas under identical condi-
tions, t-PA alone did not reduce the thrombus weight [15].
Likewise, cotreatment with a small-molecule TAFIa inhibi-
tor, BX 528, enhanced the thrombolytic effects induced by
exogenous t-PA in three animal models [16]. The same study
also reported less bleeding complications upon co-adminis-
tration of a TAFIa inhibitor compared with conventional
therapy [16].
Even although TAFIa is a very potent antifibrinolytic
enzyme, no physiological inhibitors are known. Nevertheless,
TAFIa is regulated by its intrinsic, temperature-dependent
instability (i.e. functional half-life of TAFIa is 5–15 min at
37 C) [17]. Recently, a stable TAFI variant [i.e. TAFI-A147-
C305-I325-I329-Y333-Q335 (TAFI-ACIIYQ)] has been reported
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with a 180-fold longer half-life and a 18-fold higher antifibrin-
olytic potential compared with TAFI-wt [18].
So far, several inhibitors of TAFIa have been characterized:
chelating and reducing agents [3,19], arginine and lysine
analogs [4,20] and naturally occurring metallocarboxypepti-
dase inhibitor isolated from potato (PTCI) [6]. Also small
synthetic inhibitors have been developed [16,21–25]. To
circumvent problems of specificity, monoclonal antibodies
(mAbs) have been raised against TAFI [26–28]. Some of these
mAbs interfere with the activation of TAFI whereas others
interfere directly with the catalytic activity of TAFIa. However,
therapy with murine antibodies encounters well-known prob-
lems of immunogenicity. Even although this can be circum-
vented by the generation of smaller derivatives such as single-
chain variable fragments [29] or by humanization [30], these
derivatives may encounter other difficulties such as reduced
affinity [31], aggregation and proteolysis [32].
Serum of Camelideae contains an important fraction of
functional antibodies that are naturally devoid of light chains,
called heavy-chain antibodies [33]. These heavy-chain antibod-
ies therefore recognize the antigen by a single variable-domain
heavy-chain (termed VHH or NanobodyTM). These nanobod-
ies have many inherent, advantageous properties, such as their
low molecular mass (15 kDa), low immunogenicity [34], high
affinity, high solubility and stability [35] and easy production of
the recombinant VHH in bacteria or yeast [36,37]. The
hypervariable regions [i.e. complementary determining regions
(CDR)] of nanobodies are on average longer than those of
conventional antibodies, most probably to compensate for the
loss of the binding regions on the light chain. Nanobodies are
often potent enzyme inhibitors, due to their long CDR3
domain, that often forms an extended loop and therefore is
able to penetrate into the catalytic cleft of enzymes [38]. Taken
together, these characteristics led us to hypothesize that the
generation and selection of nanobodies towards TAFI(a)might
be a successful approach to develop potent TAFI(a) inhibitors.
Here we report the generation and characterization of a
panel of 22 nanobodies raised towards TAFI and exhibiting
inhibitory properties towards various modes of TAFI activa-
tion, TAFIa activity and/or TAFI zymogen activity thereby
representing a high diversity in functional properties.
Materials and methods
Materials
Wild-type recombinant TAFI-T147-I325 (TAFI-TI), one of the
naturally occurring TAFI isoforms, TAFI-A147-C305-I325-I329
(TAFI-ACII) and TAFI-A147-C305-I325-I329-Y333-Q335 (TAFI-
ACIIYQ) were prepared as described previously [26]. All
experiments in this study were performed with TAFI-TI, unless
otherwise indicated. Oligonucleotides used for cloning and
sequencing were obtained from Sigma-Aldrich (St Louis, MO,
USA),Pfx50DNApolymerase was purchased from Invitrogen
(Merelbeke, Belgium) and restriction enzymes were provided
by New England Biolabs (Hertfordshire, UK). Polymerase
chain reactions (PCR) were carried out with the Mastercycler
Gradient from Eppendorf (Hamburg, Germany). Plasmid
DNA purification was performed with the NucleobondTM
AX500 kit (Machery-Nagel, Du¨ren, Germany) or the Plasmid
mini kit I (Omega Bio-Tek, Doraville, GA, USA). DNA was
sequenced with an ABI Prism 310 Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA).
Human thrombin, human plasmin and rabbit thrombomod-
ulin were purchased from Sigma-Aldrich, Enzyme Research
Labs (South Bend, UK) and American Diagnostica (Green-
wich, CT, USA), respectively. H-D-phenylalanyl-L-prolyl-L-
arginine chloromethyl ketone (PPACK), aprotinin, hippuryl-L-
arginine and PTCI were obtained from Biomol Research Labs
(Plymouth Meeting, PA, USA), Fluka (Buchs, Switzerland),
Bachem (Bubendorf, Switzerland) and Calbiochem (La Jolla,
CA, USA), respectively. Tissue-type plasminogen activator
(Actilyse)was akindgift fromBoehringer Ingelheim (Brussels,
Belgium). Citrated plasma of 16 healthy individuals, collected
with their written consent, was pooled for clot lysis experiments.
Thrombin and plasmin substrates (S-2238 and S-2403) were
obtained from Nodia/Chromogenix (Antwerp, Belgium).
Construction of the nanobody library and expression and
purification of binders
An alpaca (Vicugna pacos) was immunized through seven
subcutaneous injections, at weekly intervals, of 100 lg of a
stable TAFI variant (TAFI-A147-C305-I325-I329) mixed with
Gerbu adjuvant [39]. Blood was collected and peripheral blood
lymphocytes were prepared with Lymphoprep (Axis-Shield,
Norway). Construction of the VHH library was performed as
described previously [40]. The phage-displayed library was used
for two parallel pannings against another stable variant, TAFI-
A147-C305-I325-I329-Y333-Q335, either in its proenzyme form or in
its activated form, according to the protocol described by
Conrath et al. [40]. Identification of positive clones was
performed by ELISA and identical clones were identified by
sequencing. Then, the VHH genes of the positive clones were
recloned in the pHEN6expression vector usingBstEII andPstI.
The constructs were transformed in Escherichia coliWK6 cells
and expression was obtained according to the procedure as
described previously [40]. The periplasmic extract was dialyzed
against 20 mmol L)1 Tris-HCl containing 0.5 mol L)1 NaCl
(pH 7.9), loaded on a His-Trap HP column (GE Healthcare,
Uppsala, Sweden) and bound proteins were eluted using an
imidazolegradient (0–350 mmol L)1 imidazole in20 mmol L)1
Tris–HCl, 0.5 mol L)1 NaCl, pH 7.9). The nanobody contain-
ing fractions were pooled and dialyzed against phosphate-
buffered saline (PBS; 140 mmol L)1 NaCl, 2.7 mmol L)1 KCl,
8 mmol L)1 Na2HPO4, 1.5 mmol L
)1 KH2PO4; pH 7.4).
Evaluation of the overall inhibitory effect of the nanobodies
on TAFI activation and TAFIa activity
The overall inhibitory effect was measured as described earlier
with some minor modifications [26]. Purified TAFI
Inhibitory nanobodies against TAFI 1303
 2010 International Society on Thrombosis and Haemostasis
(45 nmol L)1, concentration at activation step) in HEPES
buffer (25 mmol L)1 HEPES, 137 mmol L)1 NaCl,
3.5 mmol L)1 KCl, + 0.1% BSA; pH 7.4) was incubated
(10 min at 25 C) with either buffer or nanobody (32-fold
molar excess over TAFI or a concentration ranging from 0.5-
to 32-fold) prior to activation by thrombin, thrombomodulin
and CaCl2 (concentrations at activation step: 20, 5 and
7.5 mmol L)1, respectively). After 10 min at 25 C, PPACK
(concentration to stop the activation reaction: 37.5 lmol L)1)
and the substrate hippuryl-arginine (Hip-Arg; concentration
during substrate conversion: 4 mmol L)1) was added to the
activation mixtures and substrate conversion was allowed to
proceed for 10 min at 25 C. Reaction mixtures (100 lL) were
stopped by addition of 20 lL HCl (1 mol L)1) followed by
neutralization with 20 lL NaOH (1 mol L)1) and buffered
with 25 lL Na2HPO4 (1 mol L
)1; pH: 7.4). Subsequently, 6%
cyanuric chloride, dissolved in 1,4-dioxane (30 lL), was added
and themixture was vortexed and centrifuged. The supernatant
was transferred into a 96-well microtiter plate and the
absorbance at 405 nm was measured. From the comparison
of the enzymatic activity of TAFIa generated in the absence
and in the presence of nanobody, the inhibiting capacity of the
nanobody (Nb) was calculated and expressed as percentage
inhibition {([OD]noNb- [OD]withNb)/([OD]noNb) · 100 = %
inhibition}. Reduced TAFIa activity as detected in this
experimental setup can be caused either by interference with
the activation mechanism or by direct interference with the
TAFIa enzymatic activity.
A similar method was applied for the evaluation of the
effect of the nanobodies on the plasmin-mediated activation,
except for (i) the use of plasmin (concentration at activation
step: 500 nmol L)1) instead of thrombin/thrombomodulin (T/
TM), (ii) addition of aprotinin (concentration to stop activa-
tion: 125 U mL)1) and (iii) incubation with Hip-Arg for
25 min.
As thrombin is a very weak activator of TAFI and because a
prolonged activation time is counteracted by the instability of
TAFIa (resulting in TAFIa levels that are too low to allow a
reliable quantitative evaluation of the nanobody effects) an
adaptedmethod was designed for the evaluation of the effect of
the nanobodies on the thrombin-mediated activation, for
example TAFI was replaced by TAFI-A147-C305-I325-I329-Y333-
Q335 (concentration at activation step: 45 nmol L)1), thrombin
was used at a higher concentration (concentration at activation
step: 100 nmol L)1) and no thrombomodulin was added. The
activation reaction was allowed to proceed for 2 h. Substrate
conversion (10 min) and activity measurement was performed
as described above.
Evaluation of the effect of the nanobodies on the activation of
TAFI to TAFIa
TAFI (concentration at activation step: 0.41 lmol L)1 in Tris
buffer; 20 mmol L)1 Tris, 100 nmol L)1 NaCl, pH 7.4) was
incubated with either buffer or nanobody (sixteenfold molar
excess over TAFI) for 10 min at 37 C prior to activation with
thrombin, thrombomodulin and CaCl2 (concentration at
activation step: 23.1, 5.8 and 5.8 mmol L)1, respectively).
The reactions were stopped by adding PPACK (34.5
lmol L)1) and sodium dodecyl sulfate (SDS) (1% final
concentration) to the reaction mixtures followed by heating
for 30 s at 100 C. The generated fragments were analyzed by
SDS–polyacrylamide gel electrophoresis (PAGE), using Phast-
GelTM gradient 10–15% gels, followed by silver staining.
Evaluation of the direct inhibitory effect of the nanobodies on
TAFIa activity
To determine the direct inhibitory effect of the nanobodies on
TAFIa activity, TAFI (concentration during activation:
45 nmol L)1, in HEPES buffer) was activated by thrombin/
thrombomodulin (concentration of thrombin and thrombo-
modulin during activation: 20 and 5 nmol L)1, respectively)
at 25 C prior to incubation (10 min) with an equal volume
of either buffer or nanobody (thirty-two-fold molar excess
over TAFI or a concentration ranging from 0.5- to thirty-
two-fold) as described earlier [26]. Quantification of the
residual TAFIa was determined using the substrate Hip-Arg
as described [26]. The percentage inhibition of TAFIa activity
was calculated relative to TAFIa activity in the absence of
nanobody.
Evaluation of the effect of nanobodies on the enzymatic
properties of TAFIa
Hydrolysis of Hip-Arg by TAFIa was determined in the
presence and absence of nanobody. TAFI (1 lmol L)1 in
HEPES buffer) was activated by T/TM (20 and 80 nmol L)1,
respectively) for 10 min at 25 C. Thrombin activity was
stopped by addition of PPACK (30 lmol L)1). Then nano-
body was added (molar ratio Nb: TAFI of 0.5–1) and samples
were incubated for 10 min at 25 C. Subsequently the velocity
of the substrate hydrolysis (Hip-Arg) at various concentrations
(0.125–4 mmol L)1) was monitored at 254 nm. The kcat and
KM values were determined by non-linear regression of the
data to the Michaelis–Menten equation (mean ± SD, n ‡ 4)
[39].
Evaluation of the effect of the nanobodies on the catalytic
activity of TAFI
The catalytic activity of the zymogen was determined as
described previously [41]. To determine the effect of the
nanobodies on the zymogen activity, TAFI (concentration
during substrate conversion: 0.119 lmol L)1 in HEPES buffer)
was incubated for 10 min at 37 C with either buffer or
nanobody (thirty-two-fold molar excess over TAFI) prior to
incubation with Hip-Arg (concentration during substrate
conversion: 11.1 mmol L)1). Substrate conversion was allowed
to proceed for 4 h. Evaluation of the amount of converted
substrate and quantitative evaluation of the effect of nanobody
was carried out as described above.
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Evaluation of the effect in an in vitro clot lysis experiment
Clot lysis was performed as described previously with some
small modifications [42]. Pooled plasma (30% final concentra-
tion) was mixed with buffer, nanobody or PTCI (20 lg mL)1,
final concentration). The final concentration of nanobody was
2.14 lmol L)1, resulting in a thirty-two-fold molar excess over
TAFI assuming a concentration of 178 nmol L)1 TAFI in
plasma. Alternatively, a nanobody concentration resulting in a
nanobody/TAFI ratio ranging from 0.5- to thirty-two-fold was
used. Exogenous thrombomodulin (1 nmol L)1, final concen-
tration) and tPA (90 pmol L)1) was added to the plasma. After
clot induction with CaCl2 (10.6 mmol L
)1), the plate was
incubated at 37 C and read at 405 nm at 2-min intervals to
determine the 50% clot lysis time, defined as the time from full
clot formation to the midpoint of the maximal turbid to clear
transition. Reduction of the clot lysis time was calculated
relative to the reduction of clot lysis time in the absence (0%
reduction) and presence of PTCI (20 lg mL)1, final concen-
tration; 100% reduction). Alternatively, this assay was carried
out without the addition of exogenous thrombomodulin.
Another variant of this assay was performed by adding
nanobody (or buffer or PTCI or MA-T12D11) after the clot
was formed [26]. The volume of the added solution after clot
formation was 20 lL (i.e. 20% of clot volume). The final
concentration of all components was identical to that indicated
above.
Affinity measurements
Affinity constants for the binding between nanobodies and
TAFI were determined by surface plasmon resonance (SPR)
analysis using the Biacore 3000 analytical system (Biacore AB,
Uppsala, Sweden) equipped with a CM-5 sensor chip as
described [26]. In brief, nanobodies were covalently coupled to
approximately 1200 resonance units using a concentration of
5 lg mL)1 nanobody in acetate buffer (10 mmol L)1 pH 4.5).
TAFI was diluted in HBS-EP buffer (Biacore) to concentra-
tions between 5 and 200 nmol L)1 and injected at a flow rate of
30 lL per min. After each cycle, the chip was regenerated with
10 lL of 10 mmol L)1 glycine solution pH 1.5. Analysis of the
association and dissociation phases was performed using the
Biacore 3000 software (Langmuir binding, local fit). All
experiments were performed at least three times independently.
Statistical analysis
Quantitative data were summarized by the mean and standard
deviation. Statistical analyzes on enzyme kinetics of TAFIa
were performed with one-way ANOVA.
For the sake of clarity, only values of inhibition exceeding
40%, as observed in the enzymatic assays (Table 1), were
considered as relevant for classifying the nanobodies according
to their functional properties. Using SPSS software and
appropriate analysis by pairwise comparisons between the
groups on the five inhibitory properties revealed significant
differences (P < 0.05) between these groups and confirms the
classification into eight groups (see Results).
Results
Identification of nanobodies against TAFI(a)
After immunizing an Alpaca with TAFI-A147-C305-I325-I329, we
cloned its nanobody repertoire from 9 · 107 peripheral blood
lymphocytes in a phage-display vector. Enrichment for
antigen-specific clones was performed by two parallel pannings
of this library against the stable variant, TAFI-A147-C305-I325-
I329-Y333-Q335, either in its proenzyme form (three rounds of
panning) or in its activated form (four rounds of panning). This
resulted in the selection of 18 and 12 different nanobodies,
respectively. Twenty-two out of these 30 nanobodies were
found to exhibit inhibitory properties towards TAFI activation
or TAFI(a) activity.
Nanobodies that resulted from panning against the proen-
zyme (intact TAFI) are denominated as Vhh-TAFI-i, whereas
nanobodies selected through panning against the activated
form are denominated Vhh-TAFI-a. All nanobodies were
produced in E. coli and purified by immobilized metal affinity
chromatography.
Overall inhibitory effect of nanobodies towards TAFI
Addition of nanobody prior to activation of TAFI results in
the possible detection of nanobodies interfering with either
TAFI activation or TAFIa activity or both. This assay
revealed that five nanobodies interfere with the thrombin/
thrombomodulin mediated TAFI activation and/or TAFIa
activity resulting in a 52%–100% inhibition at a thirty-two-
fold molar excess (Table 1, column 3). Four of these
nanobodies exhibited a strong inhibitory effect with values
between 95% and 100% (group 1, 2 and 3), whereas one
nanobody, Vhh-TAFI-i32, revealed only a moderate inhibition
(52.3% ± 3.2%) (group 4). It should be noted that classifi-
cation in groups (Table 1, column 3) is not solely based on the
behaviour in this particular assay, but based on the results
obtained with all assays.
Dose-response experiments were performed for the nano-
bodies with a strong inhibitory effect (group 1–3) and
demonstrate that a maximal inhibitory effect is already
observed at a 2-fold molar excess (Fig. 1A).
Nanobodies of group 1–4 were also able to inhibit thrombin-
mediated TAFI activation and/or TAFIa activity, resulting in
inhibitory properties between 62% and 99% (Table 1, column
4, group 1–4). In addition, five other nanobodies, that were not
able to interfere with TAFI when activated by T/TM, did
interfere with thrombin-mediated TAFI activation and/or
TAFIa activity resulting in inhibitory values between 43%
and 74% (Table 1, column 4, group 5 and 6). The nanobodies
of group 6 did not have an effect on thrombin activity as
evaluated with the chromogenic substrate S-2238 (data
not shown) thereby excluding that the observed effect on
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thrombin-mediated TAFI activationwould be due to thrombin
inhibition.
Evaluation of the effect on plasmin-mediated TAFI
activation and/or TAFIa activity, revealed a strong inhibition
(67%–100%) by the nanobodies of group 1, 2, 3 and 5. In
addition, nine other nanobodies (Table 1, column 5, group
7), exhibiting virtually no effect on the T/TM- and T-
mediated assays, exhibited a moderate but clearly distinct
inhibition in the plasmin-mediated assay, with values between
41% and 69%. These nanobodies did not have an effect on
plasmin activity as evaluated with the chromogenic substrate
S-2403 (data not shown), thereby excluding that the observed
effect on TAFI activation would be due to plasmin
inhibition.
All other nanobodies (Table 1, column 3–5, group 8)
exhibited no inhibitory effects (i.e. £40%), in this overall
assay, irrespective of the activator used.
Evaluation of the effect on the activation of TAFI to TAFIa
To examine the effect of the nanobodies on the activation of
TAFI, the fragmentation products generated upon activation
with T/TM (in the absence or presence of nanobody) were
analyzed. In the absence of nanobody the typical fragmen-
tation pattern was observed: disappearance of the 56-kDa
proenzyme and generation of a 36- and 25-kDa fragment
(Fig. 2, lane 2). This typical 25-kDa fragment is the
subsequent cleavage product due to a secondary cleavage
site at position Arg302 in conformationally inactivated TAFI
[1]. All nanobodies of group 1, 2 and 3, (Vhh-TAFI-i83,
Vhh-TAFI-a206, Vhh-TAFI-i108m, Vhh-TAFI-a204) ham-
pered the conversion of TAFI (55 kDa) into TAFIa
(36 kDa) virtually completely (Fig. 2, lane 3–6, respectively).
Vhh-TAFI-i32 (group 4) moderately inhibited the conversion
of TAFI into TAFIa (Fig. 2, lane 7). Vhh-TAFI-i37 (group
7) (Fig. 2, lane 8) and all other nanobodies of group 5
through to 8 (data not shown) did not affect the fragmen-
tation pattern. All data obtained in this assay are in line with
the respective properties observed in the overall inhibitory
assay (T/TM).
Direct inhibitory effect on TAFIa activity
Addition of nanobody after activation of TAFI and
subsequent evaluation of the enzymatic activity of TAFIa
allowed the detection of nanobodies that interfere directly
with TAFIa. Strikingly, only one nanobody (Vhh-TAFI-i83,
group 1) revealed a strong direct inhibitory effect (88%) on
the TAFIa activity. Two other nanobodies (Vhh-TAFI-
i108m and Vhh-TAFI-a206, group 2) revealed a moderate
inhibitory effect (46%) (Table 1, column 6). Dose-response
experiments demonstrate that Vhh-TAFI-i83 reaches its
maximal inhibitory effect at a 8-fold molar excess, whereas
for Vhh-TAFI-i108m and Vhh-TAFI-a206 the maximal
inhibitory effect was not yet reached at a thirty-two–fold
molar excess (Fig. 1B).
From the absence of any inhibitory effect of Vhh-TAFI-
a204 and Vhh-TAFI-i32 on the enzymatic activity it can be
Table 1 Effect* of nanobodies on the enzymatic properties of TAFI(a), its activation and on clot lysis times
Nanobody Group
T/TM-mediated
activation
T-mediated
activation
Plasmin-
mediated
activation
TAFIa
activity
Zymogen
activity
Profibrinolytic
effect**
Vhh-TAFI-i83 1 96 ± 0.3 87 ± 3 83 ± 2 88 ± 1 64 ± 4 83 ± 8
Vhh-TAFI-a206 2 96 ± 0.3 76 ± 3 67 ± 3 47 ± 3 52 ± 10 76 ± 7
Vhh-TAFI-i108m 2 96 ± 1 76 ± 4 77 ± 4 46 ± 2 42 ± 20 80 ± 8
Vhh-TAFI-a204 3 100 ± 1 99 ± 0.3 100 ± 1 5.1 ± 3.7 48 ± 11 100 ± 2
Vhh-TAFI-i32 4 52 ± 4 62 ± 3 9.3 ± 8.6 1.7 ± 3.2 56 ± 3 33 ± 11
Vhh-TAFI-a190 5 16 ± 7 43 ± 4 68 ± 3 )11 ± 9 10 ± 18 21 ± 6
Vhh-TAFI-a52 6 19 ± 4 45 ± 6 36 ± 18 )6.2 ± 10.9 9.7 ± 16.6 14 ± 4
Vhh-TAFI-a104 6 3.2 ± 6.1 44 ± 6 )13 ± 10 )4.3 ± 12.0 14 ± 7 3.7 ± 1.6
Vhh-TAFI-a215 6 16 ± 3 44 ± 7 32 ± 8 )14 ± 7 16 ± 24 )1.0 ± 8.2
Vhh-TAFI-i64 6 3.5 ± 2.7 74 ± 4 )0.4 ± 7.1 7.7 ± 3.8 30 ± 11 5.7 ± 15.0
Vhh-TAFI-a200 7 10 ± 4 0.3 ± 1.5 53 ± 6 )14 ± 6 6.2 ± 14.9 34 ± 8
Vhh-TAFI-a263 7 9.5 ± 4.6 )13.4 ± 6.2 56 ± 7 2.1 ± 7.8 0.3 ± 17.0 36 ± 2
Vhh-TAFI-a306 7 12 ± 4 25 ± 7 41 ± 9 )7.3 ± 3.1 21 ± 24 22 ± 4
Vhh-TAFI-a327 7 13 ± 4 )7.9 ± 2.2 57 ± 3 )0.2 ± 10.2 9.9 ± 5.7 35 ± 5
Vhh-TAFI-i7 7 9.5 ± 3.5 )1.6 ± 1.2 58 ± 5 1.3 ± 4.3 12 ± 4 27 ± 3
Vhh-TAFI-i37 7 18 ± 1 )8.9 ± 1.9 45 ± 2 5.8 ± 4.6 12 ± 7 36 ± 8
Vhh-TAFI-i109 7 14 ± 3 )4.8 ± 12.2 45 ± 8 0.6 ± 3.9 2.2 ± 11.7 35 ± 3
Vhh-TAFI-i129 7 9.4 ± 4.0 )1 ± 13 69 ± 3 )2.5 ± 7.4 )2.2 ± 16.9 23 ± 0.02
Vhh-TAFI-i135 7 8.6 ± 1.6 )6.2 ± 5.8 55 ± 3 7.2 ± 5.0 6.8 ± 12.9 24 ± 4
Vhh-TAFI-i6 8 1.9 ± 3.4 30 ± 2 )2.0 ± 5.1 9.5 ± 8.9 59 ± 6 )12 ± 11
Vhh-TAFI-i46 8 4.9 ± 6.0 19 ± 4 )0.1 ± 6.1 )1.3 ± 3.1 42 ± 6 )0.2 ± 2.0
Vhh-TAFI-i66 8 5.4 ± 2.7 28 ± 1 )6.4 ± 7.7 7.6 ± 5.0 41 ± 9 )10 ± 6
*Expressed as percentage inhibition (see methods); mean ± SD, n = 3. **Reduction of clot lysis time, caused by the nanobody, expressed as
percentage vs. the reduction caused by PTCI (100%) (see methods; mean ± SD, n ‡ 3). Values of inhibition exceeding 40% are indicated in bold.
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deduced that their effects observed in the overall inhibitory
assay are exclusively due to an impairment of the activation
step.
Effect of nanobodies on the enzymatic properties of TAFIa
Data of the hydrolysis of the substrate Hip-Arg by TAFIa in
the absence and presence of nanobodies Vhh-TAFI-i83, Vhh-
TAFI-i108m and Vhh-TAFI-a206 are shown in Fig. 3 and
Table 2. Addition of Vhh-TAFI-i83, Vhh-TAFI-i108m and
Vhh-TAFI-a206 resulted in a significant (P < 0.005) and
dose-dependent decrease of the catalytic rate (kcat). This is
observed at very low inhibitor concentrations, in the same
order of magnitude as the enzyme concentration, indicating
that these nanobodies are tight-binding inhibitors [40].
Addition of Vhh-TAFIi83 and Vhh-TAFI-a206 had no
effect on the KM-value (Table 2). In contrast, addition of Vhh-
TAFI-i108m resulted in a significant (P < 0.0001) and dose-
dependent decrease ofKM. This suggests that the substrate may
have a slightly higher affinity for the enzyme/inhibitor complex
vs. free enzyme [43] and indirectly indicates a simultaneous
binding of Vhh-TAFI-i108m and Hip-Arg to TAFIa.
Effect of nanobodies on the catalytic activity of the
proenzyme TAFI
To evaluate the possible effect of the nanobodies on the
catalytic activity of the zymogen, nanobodies were incubated
with intact TAFI prior to incubation with Hip-Arg (and
without activation with thrombin, T/TM or plasmin). Vhh-
TAFI-i83, Vhh-TAFI-i108m, Vhh-TAFI-a206, Vhh-TAFI-
a204 and Vhh-TAFI-i32 (group 1–4) exhibited a moderate
inhibitory effect (42%–64%) on the zymogen activity (Table 1,
column 7). In addition, three other nanobodies that exhibited
no inhibition on TAFIa activity or TAFI activation (Table 1,
column 7, group 8) revealed a moderate inhibition of the
Fig. 1. Dose-dependent effect of Vhh-TAFI-i83 ( , black full line), Vhh-
TAFI-a206 (., black dashed line), Vhh-TAFI-i108m (•, black dotted line)
and Vhh-TAFI-a204 ( , gray full line) on thrombin/thrombomodulin (T/
TM)-mediated thrombin-activatable fibrinolysis inhibitor (TAFI) activa-
tion (A), activated thrombin-activatable fibrinolysis inhibitor (TAFIa)
activity (B) and 50% clot lysis times (C). Percentage inhibition was cal-
culated relative to TAFI activation or TAFIa activity in the absence of
nanobody (=100% activation/activity). Percentage reduction of 50% clot
lysis time was calculated as percentage relative the reduction caused by
potato tuber carboxypeptidase inhibitor (PTCI) (=100% reduction). The
results represent mean ± SD (n ‡ 3).
Fig. 2. Effect of nanobodies on fragmentation pattern of thrombin-
activatable fibrinolysis inhibitor (TAFI) upon activation by thrombin/
thrombomodulin (T/TM). Sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) of TAFI, pre-incubated with buffer (lane
1and 2), or Vhh-TAFI-i83 (lane 3), Vhh-TAFI-a206 (lane 4), Vhh-
TAFI-i108m (lane 5), Vhh-TAFI-a204 (lane 6), Vhh-TAFI-i32 (lane 7),
Vhh-TAFI-i37 (lane 8) prior to activation with T/TM (lanes 2–8). Intact
TAFI (56 kDa) is indicated by the arrow, activated thrombin-activatable
fibrinolysis inhibitor (TAFIa) (36 kDa) by the dashed arrow, the 25 kDa
fragment by the open arrowhead and the nanobody (15 kDa) by the
arrowhead.
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zymogen activity (41%–59%). All other nanobodies (group
5–7) exhibited no inhibitory effect in this assay (Table 1,
column 7).
Effect of nanobodies in an in vitro clot lysis experiment
To test the functional effects of the nanobodies on clot lysis,
plasma was preincubated with buffer (negative control), PTCI
(reference) or nanobody. For the negative control and the
reference, 50% clot lysis times of 91–120 and 54–65 min,
respectively, were obtained in the presence of TM. In the
absence of TM, 50% clot lysis times of 76–100 and 37–56 min
were obtained for the negative control and the reference,
respectively. Vhh-TAFI-i83, Vhh-TAFI-i108m, Vhh-TAFI-
a206 and Vhh-TAFI-a204 (group 1–3) strongly reduced
(76%–100%) the clot lysis times, whereas addition of nano-
bodies of group 4 (interferingmoderately with T/TM- and with
T-mediated activation and also with the intrinsic activity),
group 5 (interfering predominantly with plasmin-mediated
activation) and group 7 (interfering exclusively with plasmin-
mediated activation), resulted in a minor reduction (21%–
36%) of clot lysis times (Table 1). None of the other
nanobodies (i.e. group 6 and 8) reduced clot lysis. Dose-
response curves were performed for the nanobodies with the
most pronounced effect on clot lysis (i.e. group 1–3). These
data demonstrate that the maximal profibrinolytic effect is
virtually reached at a 2- to 4-fold molar excess (Fig. 1C).
In the above-mentioned typical clot lysis experiments, TAFI
inhibitors were added prior to clot formation. To evaluate the
value of a TAFI inhibitor added after clot formation and the
effect of the size of the inhibitor under those conditions, the
nanobody Vhh-TAFI-a204 and the inhibitory monoclonal
antibody MA-T12D11, added after clot formation, were
subjected to a comparative evaluation. Addition of Vhh-
TAFI-a204 after clot formation still yielded a reduction of the
clot lysis time of 54% ± 5% (vs. 99% when added prior to
clot formation, Table 1), whereas the inhibitory monoclonal
antibodyMA-T12D11 yielded a reduction of only 21% ± 8%
(Fig. 4) (vs. 92%–98% when added prior to clot formation
[26,44]).
Thrombomodulin is a strong accelerator of TAFI activation.
The presence of exogenously added TM in a typical clot lysis
experiment could, therefore, obscure effects of inhibitory
nanobodies that do not or only moderately interfere with T/
TM-mediated activation (group 4, 5, 6 and 7) or interfere
exclusively with the zymogen activity (group 8). Therefore,
these nanobodies were evaluated in a clot lysis assay to which
no exogenous thrombomodulin was added. Nanobody Vhh-
TAFI-i32 (moderate interference with T/TM- and T-mediated
activation and with zymogen activity, group 4), Vhh-TAFI-
a190 (only interference with T- and with plasmin-mediated
activation, group 5) and nanobodies from group 7 (only
interference with plasmin-mediated activation) resulted in a 2-
fold increased reduction of clot lysis time in the absence of
exogenously added TM compared with that observed in the
presence (45%–59% reduction vs. 21%–36% reduction,
respectively). The effect observed with nanobodies of group 6
(exclusive interference with T-mediated activation) and of
group 8 (mainly interfering with zymogen activity) was
virtually independent of the absence or presence of exogenously
Fig. 3. Michaelis–Menten curves of Hip-Arg hydrolysis by activated
thrombin-activatable fibrinolysis inhibitor (TAFIa) in the absence or
presence of nanobody. (A) Vhh-TAFI-i83 at a molar ratio Nb:TAFI of 0
(., full line), 0.5 ( , dotted line) and 0.75 ( , dashed line), (B) Vhh-TAFI-
a206 at a molar ratio Nb:TAFI of 0 (., full line), 0.5 ( , dotted line) and 1
( , dashed line), (C) Vhh-TAFI-i108m at a molar ratio Nb:TAFI of 0 (.,
full line), 0.5 ( , dotted line) and 1 ( , dashed line).
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added TM ()21%–20% vs. )12%–14%). The profibrinolytic
effect of Vhh-TAFI-a204, included as a positive control, was
fully conserved in the absence of exogenously added TM
(101% ± 6% vs. 99.5% ± 2.0% in the presence of TM).
Affinity of nanobodies towards TAFI
Evaluation of the binding between TAFI and some selected
nanobodies was performed by surface plasmon resonance
analysis. A high affinity for TAFI (KA–values between 1 and
5 nM)1) was observed for the nanobodies of group 1, 2 and 3
(Table 3). Nanobodies of group 4, 5, 7 and 8,revealed a lower
affinity towards TAFI (KA–values between 3 and 24 nM
)1),
mainly caused by high dissociation kinetics (kd in the order of
10)2 per seconds), except for Vhh-TAFI-i6, for which the lower
affinity is the consequence of both a decreased association and
dissociation kinetics. For a yet unknown reason no detectable
binding was observed for Vhh-TAFI-i64 in these experiments;
however, binding of Vhh-TAFI-i64 to TAFI was confirmed by
ELISA (data not shown).
Discussion
TAFI hampers fibrinolysis by removing carboxy-terminal
lysines from partially degraded fibrin. Removal of the lysine
residues, a cofactor in the formation of the ternary complex of
plasminogen and t-PA, results in a decreased plasmin forma-
tion and an inhibition of clot lysis. This function of TAFI
makes it an attractive target for the development of new
fibrinolytic drugs. Moreover, current established thrombolytic
treatment with new generation plasminogen activators did not
appear to circumvent the several side effects of tPA so major
bleedings stays a serious complication of thrombolytic therapy
[45]. Coadministration of a TAFI inhibitor might reduce
complications and improve thrombolytic efficacy [13,14]. To
date, several TAFI inhibitors have been generated
[12,16,23,25,26,46,47]; however, small synthetic inhibitors often
deal with a lack of specificity [48]. On the other hand,
therapeutic use of monoclonal antibodies can cause immuno-
genicity problems. Nanobodies are the smallest antigen-bind-
ing antibody fragments and have superior features, such as
high solubility and high stability because they are natural
monomeric antigen binders [49]. It was previously demon-
strated that nanobodies are often very potent enzyme inhibitors
[40]. Therefore, and as a novel approach for the development of
TAFI(a) inhibitors, we generated nanobodies.
Indeed, after immunization and panning with stable variants
of TAFI, a panel of 22 inhibitory nanobodies was obtained.
Importantly, this panel represents a wide diversity in modes of
action of interference with the TAFI properties. These 22
nanobodies could be classified into eight different categories: (i)
interfering with all mechanisms of activation, with the TAFIa
activity and with the zymogen activity; (ii) interfering with all
mechanisms of activation and only moderately with TAFIa
activity and zymogen activity; (iii) interfering with all mecha-
nisms of activation and moderately with zymogen activity but
not with TAFIa activity; (iv) moderately interfering with T/
TM- and T-mediated TAFI activation and zymogen activity
but not with plasmin-mediated TAFI activation and TAFIa
activity; (v) moderately interfering with T- and plasmin-
mediated TAFI activation but not with T/TM-mediated TAFI
activation, TAFIa activity and zymogen activity; (vi) exclu-
sively interfering with T-mediated TAFI activation; (vii)
exclusively interfering with plasmin-mediated TAFI activation;
and (viii) exclusively interfering with zymogen activity.
Surprisingly, one nanobody, Vhh-TAFI-i83, strongly inhib-
its the activation of TAFI, for example preventing the
proteolytic cleavage of the Arg92-Ala93 bound, as well as the
carboxypeptidase activity of activated TAFI (TAFIa), for
Table 2 Enzyme kinetics of Hip-Arg hydrolysis by TAFIa in the absence and presence of Vhh-TAFI-i83, Vhh-TAFI-a206 and Vhh-TAFI-i108m
Molar ratio
(Nb: TAFI) KM (mmol L
)1) kcat (s
)1) kcat/KM (mM
)1 s)1)
0 1.21 ± 0.26 12.5 ± 2.04 10.6 ± 1.90
Vhh-TAFI-i83 0.5 0.881 ± 0.435 7.17 ± 2.76* 8.48 ± 0.93**
0.75 1.19 ± 0.79 5.05 ± 3.49* 4.67 ± 1.96**
Vhh-TAFI-a206 0.5 1.41 ± 0.864 8.98 ± 3.93*** 6.94 ± 1.88***
1 0.896 ± 0.286 3.42 ± 1.55*** 3.98 ± 1.58***
Vhh-TAFI-i108m 0.5 0.681 ± 0.279*** 7.20 ± 1.83*** 11.6 ± 2.95
1 0.192 ± 0.119*** 2.12 ± 0.37*** 16.1 ± 10.2
Mean ± SD; n ‡ 4. *P < 0.002, **P < 0.0005 and ***P < 0.0001 (one-way ANOVA).
Fig. 4. Effect of the size of thrombin-activatable fibrinolysis inhibitor
(TAFI) inhibitor (added after clot formation) on clot lysis. The arrow
indicates the time point of addition of potato tuber carboxypeptidase
inhibitor (PTCI) (s), Vhh-TAFI-a204 ( ),MA-T12D11 (h) or buffer ( ).
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example interfering with the residues of the enzymatic pocket
(residues implicated in catalysis: Arg217 andGlu363; in substrate
binding: Arg235, Tyr341 and Asn234; in zinc binding: His159,
Glu162 and His288). As Vhh-TAFI-i83 also interferes with the
zymogen activity it is most likely that this nanobody binds
directly into the catalytic cleft of TAFI(a). We do suggest that
its effect on the activation is due to a subsequently induced
conformational change/allosteric modulation of the region
comprising the Arg92-Ala93 bound. This hypothesis is also
further substantiated by the observation that Vhh-TAFI-i83
impairs the activation irrespective of the activator used. Not
surprisingly, the multi-inhibitory properties of Vhh-TAFI-i83,
together with its high affinity (KA = 5 · 109 M)1) results in a
strong profibrinolytic effect in clot lysis. To our knowledge, this
is the first TAFI inhibitor that exhibit strong inhibitory
properties towards the various modes of TAFI activation, as
well as towards TAFIa activity and the zymogen activity.
Analysis of the enzyme kinetics of Hip-Arg hydrolysis by
TAFIa in the absence and presence of Vhh-TAFI-i83, Vhh-
TAFI-a206 and Vhh-TAFI-i108m (nanobodies that inhibit
TAFIa activity) reveals that these nanobodies are tight-binding
inhibitors, as has been reported for other nanobodies [40]. This
is compatible with their high affinity as observed by surface
plasmon resonance analysis. The effect of Vhh-TAFI-i108m on
KM suggests that this nanobody exerts its inhibitory effect
through a different mechanism compared with that of Vhh-
TAFI-i83 and Vhh-TAFI-a206.
In the currently used clot lysis model, four nanobodies
exerted a strong acceleration of the lysis time, comparable to
that of PTCI, indicating a complete knock-out of TAFI(a). It
should be noted that this functional model is strongly TM
dependent and yields data (Table 1) that are in line with the
observation that these four nanobodies are very potent
inhibitors of the T/TM-mediated TAFI activation (Table 1).
On the other hand all other nanobodies with virtually no effect
on clot lysis do not interfere with the T/TM-mediated
activation. As TM accelerates the T-mediated TAFI activation
one thousand two hundred and fifty-fold [5,47], it could be
expected that in clot lysis experiments performed in the
presence of TM, the latter nanobodies had no effect. However,
comparison of the effects on clot lysis in the absence of
exogenously added TM, observed for nanobodies of group 5
and 7 (no effect on T/TM mediated activation but a
pronounced effect on plasmin-mediated activation) with those
observed for nanobodies of group 6 (only a pronounced effect
on T-mediated activation, no effect on T/TM- nor on plasmin-
mediated activation), is strongly suggestive for a significant role
of plasmin-mediated activation of TAFI during clot lysis. This
is indicative for a dual role of plasmin during fibrinolysis:
fibrinolytic due to its fibrin degradation properties on the one
hand, but antifibrinolytic due to its capability to activate TAFI.
The relative contribution of the various TAFI activators in vivo
is currently not known. Our results demonstrate that nano-
bodies which exclusively interfere with plasmin-mediated
activation (i.e. group 7) may constitute useful tools to further
unravel the relative contribution of each of the physiological
activators. In this respect it is important to realize that TAFI is
not only implicated in fibrinolysis but also plays a role in
inflammation, cell migration and blood pressure [9–12],
processes in which plasmin- rather than T/TM-mediated
activation may be involved.
To the best of our knowledge this is the first report
identifying TAFI inhibitors that interfere exclusively with the
TAFI zymogen activity. Even although there is a report
suggesting a physiological role for TAFI zymogen activity [50],
our data are in line with the suggestion that TAFI zymogen
activity does not play a major role in fibrinolysis [51] as these
nanobodies have no or no pronounced effect on clot lysis
experiments, neither in the presence nor in the absence of TM.
An additional, important advantage for potential therapeu-
tic application of nanobodies is their ten-fold smaller size
compared with conventional monoclonal antibodies. We,
therefore, anticipated that TAFI inhibitory nanobodies may
penetrate the clot more efficiently than TAFI inhibitory
monoclonal antibodies. Indeed, whereas Vhh-TAFI-a204 and
MA-T12D11 have a similar affinity (KA 1.4 · 109 and
5 · 109 M)1, respectively) and affect clot lysis to a similar
extent when added prior to clot formation, the profibrinolytic
effect of the nanobody was only 2-fold reduced when added
after clot formation, in contrast to the effect of MA-T12D11
that was 4-fold reduced. These data strongly suggest that the
inhibitory nanobodies do better penetrate into the clot and as
such may constitute a better therapeutic agent for for example
adjunctive therapy during thrombolytic treatment.
Table 3 Binding parameters for nanobodies towards TAFI
Nanobody Group ka (M
)1 s)1) kd (s
)1) KA (M
)1)
Vhh-TAFI-i83 1 2.50 ± 0.20 · 105 4.74 ± 0.04 · 10)5 5.31 ± 1.19 · 109
Vhh-TAFI-i108m 2 2.98 ± 0.07 · 105 1.67 ± 0.03 · 10)4 1.95 ± 0.46 · 109
Vhh-TAFI-a206 2 1.70 ± 0.21 · 105 1.76 ± 0.03 · 10)4 9.80 ± 2.48 · 108
Vhh-TAFI-a204 3 1.31 ± 0.28 · 106 9.23 ± 0.20 · 10)4 1.42 ± 0.68 · 109
Vhh-TAFI-i32 4 1.18 ± 0.19 · 105 3.50 ± 0.51 · 10)2 3.24 ± 3.15 · 106
Vhh-TAFI-a190 5 2.88 ± 0.35 · 105 1.58 ± 0.06 · 10)2 1.72 ± 1.03 · 107
Vhh-TAFI-i64 6 NB NB NB
Vhh-TAFI-a327 7 2.88 ± 0.90 · 105 1.18 ± 0.09 · 10)2 2.40 ± 1.44 · 107
Vhh-TAFI-i129 7 3.35 ± 1.20 · 105 2.03 ± 0.13 · 10)2 1.82 ± 1.13 · 107
Vhh-TAFI-i6 8 4.10 ± 0.62 · 104 2.34 ± 0.17 · 10)3 1.79 ± 0.58 · 107
Mean ± SD; n = 3. NB, no binding; KA < 10
6
M
)1.
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